Deucravacitinib for Psoriatic Arthritis
Trial Summary
What is the purpose of this trial?
This trial is testing a new medication called deucravacitinib to see if it can help people with psoriatic arthritis who haven't tried advanced treatments. The medication works by reducing joint swelling and pain by blocking inflammation. Deucravacitinib is a new oral drug that has shown good results in previous studies for psoriasis.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. Please consult with the trial coordinators for more details.
What data supports the effectiveness of the drug deucravacitinib for psoriatic arthritis?
In a phase II clinical trial, deucravacitinib showed sustained effectiveness in treating psoriatic arthritis, particularly in reducing symptoms like arthritis, enthesitis (inflammation where tendons or ligaments attach to bone), and dactylitis (swelling of fingers or toes). It was well tolerated and had a favorable safety profile, making it a promising option for managing psoriatic arthritis.12345
Is Deucravacitinib safe for humans?
How is the drug deucravacitinib unique for treating psoriatic arthritis?
Deucravacitinib is unique because it is a first-in-class, oral drug that selectively inhibits tyrosine kinase 2 (TYK2), a protein involved in the immune response that contributes to psoriatic arthritis. This specific targeting may offer a new option for patients who do not respond well to existing treatments.12689
Research Team
Bristol-Myers Squibb
Principal Investigator
Bristol-Myers Squibb
Eligibility Criteria
This trial is for individuals with active psoriatic arthritis who haven't used biologic disease-modifying anti-rheumatic drugs. They should have at least 3 swollen and tender joints, a diagnosis of PsA for 3+ months, an active skin lesion or history of plaque psoriasis, and certain levels of inflammation markers in their blood.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either deucravacitinib or placebo to evaluate efficacy and safety
Follow-up
Participants are monitored for safety and effectiveness after treatment
Long-term extension
The long term extension period will provide additional long-term efficacy and safety information
Treatment Details
Interventions
- Deucravacitinib
- Placebo
Deucravacitinib is already approved in United States, European Union, Canada for the following indications:
- Moderate to severe plaque psoriasis
- Moderate to severe plaque psoriasis
- Moderate to severe plaque psoriasis
Find a Clinic Near You
Who Is Running the Clinical Trial?
Bristol-Myers Squibb
Lead Sponsor
Christopher Boerner
Bristol-Myers Squibb
Chief Executive Officer since 2023
PhD in Business Administration from the Haas School of Business, University of California, Berkeley; BA in Economics and History from Washington University in St. Louis
Deepak L. Bhatt
Bristol-Myers Squibb
Chief Medical Officer since 2024
MD from Yale University; MSc in Clinical Epidemiology from the University of Pennsylvania